Suppr超能文献

Ad-KDRscFv:sTRAIL 表现出协同抗肿瘤作用,对正常组织无明显细胞毒性。

Ad-KDRscFv:sTRAIL displays a synergistic antitumor effect without obvious cytotoxicity to normal tissues.

机构信息

Department of Gastroenterology, Southwest Hospital, Third Military Medical University, Chongqing, P.R. China.

出版信息

Int Immunopharmacol. 2012 May;13(1):37-45. doi: 10.1016/j.intimp.2012.02.006. Epub 2012 Mar 9.

Abstract

AIM

To investigate the antitumor activities and safety of Ad-KDRscFv, Ad-sTRAIL (114-281) and Ad-KDRscFv:sTRAIL in vivo and in vitro.

METHODS

Recombinant replication-defective adenovirus vectors encoding either the extracellular domain (114-281 aa) of TRAIL, the KDRscFv (single chain antibody (scFv) against human vascular endothelial growth factor (VEGF) receptor KDR) or the fusion gene of KDRscFv:sTRAIL were constructed and transfected into HEK 293 cells for virus packaging. The recombinant virus particles were then infected human tumor cell lines of liver cancer (HepG2), gastric cancer (SGC-7901), colorectal cancer (SW480) and normal human liver cell line (LO2) to investigate the antitumor activities. Nude mice of the subcutaneous tumor models were established with HepG2 cells and were randomly divided into different groups to investigate the therapeutic effect and safety of these adenovirus particles on hepatocellular carcinoma. The expression of foreign proteins and the effect on microvascular number were also evaluated.

RESULTS

All three adenovirus particles could induce apoptosis of cancer cells lines HepG2, SGC-7901 and SW480, but had no obvious lethal effect on LO2 cells. Ad-KDRscFv:sTRAIL showed the strongest tumoricidal effect. After intratumoral injection with these adenovirus particles on nude mice model, all the three adenoviruses could inhibit the tumor growth and angiogenesis, and the expression of foreign proteins (sTRAIL, KDRscFv and KDRscFv:sTRAIL fusion protein) was restricted to liver and tumor tissues. In coincidence with the result in vitro, Ad-KDRscFv:sTRAIL also had the strongest antitumor activity in vivo. No obvious pathological changes were detected in vivo.

CONCLUSIONS

Replication-defective recombinant adenovirus of Ad-KDRscFv, Ad-sTRAIL and Ad-KDRscFv:sTRAIL all had tumoricidal activities and Ad-KDRscFv:sTRAIL showed the strongest effect. All three adenoviruses had no obvious toxicity to normal cells and tissues in vitro and in vivo.

摘要

目的

研究 Ad-KDRscFv、Ad-sTRAIL(114-281)和 Ad-KDRscFv:sTRAIL 在体内和体外的抗肿瘤活性和安全性。

方法

构建并转染编码 TRAIL 细胞外结构域(114-281 aa)、KDRscFv(针对人血管内皮生长因子(VEGF)受体 KDR 的单链抗体(scFv))或 KDRscFv:sTRAIL 融合基因的重组复制缺陷型腺病毒载体,用于病毒包装。然后将重组病毒颗粒感染肝癌(HepG2)、胃癌(SGC-7901)、结直肠癌(SW480)和正常人类肝细胞系(LO2)的人肿瘤细胞系,以研究其抗肿瘤活性。用 HepG2 细胞建立裸鼠皮下肿瘤模型,并随机分为不同组,以研究这些腺病毒颗粒对肝癌的治疗效果和安全性。还评估了外源蛋白的表达及其对微血管数量的影响。

结果

三种腺病毒颗粒均能诱导 HepG2、SGC-7901 和 SW480 癌细胞系凋亡,但对 LO2 细胞无明显致死作用。Ad-KDRscFv:sTRAIL 显示出最强的杀瘤作用。在裸鼠模型中瘤内注射这些腺病毒颗粒后,所有三种腺病毒均可抑制肿瘤生长和血管生成,并且外源蛋白(sTRAIL、KDRscFv 和 KDRscFv:sTRAIL 融合蛋白)的表达仅限于肝脏和肿瘤组织。与体外结果一致,Ad-KDRscFv:sTRAIL 在体内也具有最强的抗肿瘤活性。体内未检测到明显的病理变化。

结论

Ad-KDRscFv、Ad-sTRAIL 和 Ad-KDRscFv:sTRAIL 的复制缺陷型重组腺病毒均具有杀瘤活性,Ad-KDRscFv:sTRAIL 作用最强。三种腺病毒在体外和体内对正常细胞和组织均无明显毒性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验